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Abstract
Background: Apolipoprotein M (apoM) is mainly enriched in high-density lipoprotein (HDL) cholesterol and is
slightly present in low-density lipoprotein (LDL) cholesterol and very low-density lipoprotein cholesterol. apoM
is involved in HDL formation and HDL-mediated reverse cholesterol transport. apoM is also associated with
hyperlipidaemia and type 2 diabetes mellitus (T2DM). Significantly high plasma apoM levels are detected in
hyperlipidaemia mice with a defective LDL receptor. By contrast, low plasma apoM levels are observed in patients with
T2DM, which is often accompanied with hyperlipidaemia. However, the underlying mechanism of this condition is
poorly understood. This research aims to examine the changes in apoM levels in patients with hyperlipidaemia and to
determine the effects of hyperlipidaemia on plasma apoM levels in patients with T2DM.
Methods: This study included patients with hyperlipidaemia (n = 79), patients with T2DM but without hyperlipidaemia
(n = 125), patients with T2DM and hyperlipidaemia (n = 98), and healthy controls (n = 105). Their plasma apoM
concentrations were measured with enzyme-linked immunosorbent assay.
Results: The average plasma apoM concentrations were 18 % higher in the hyperlipidaemia group (26.63 ±
10.35 ng/μL) than in the healthy controls (22.61 ± 10.81 ng/μL, P <0.01). The plasma apoM concentrations
were lower in the T2DM without hyperlipidaemia group (18.54 ± 10.33 ng/μL, P <0.01) and the T2DM with
hyperlipidaemia group (19.83 ± 7.41 ng/μL, P <0.05) than in the healthy controls. Similar to apoA-I (1.29 ± 0.
33 g/L vs. 1.28 ± 0.31 g/L, P >0.05), the plasma apoM concentrations in the T2DM with hyperlipidaemia group
did not significantly differ from those in the T2DM without hyperlipidaemia group (P >0.05). Multivariate linear
regression analysis showed that hyperlipidaemia (β = 5.18, P = 0.007) is an independent promoting factor of
plasma apoM levels and diabetes (β = −3.09, P = 0.005) is an inhibiting factor of plasma apoM levels.
Conclusion: Plasma apoM concentrations are higher in patients with hyperlipidaemia than in healthy controls.
Low plasma apoM levels in patients with T2DM are likely caused by diabetes but are not induced by hyperlipidaemia.
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Background
Apolipoprotein M (apoM) is a 25 kDa plasma protein
containing 188 amino acids and belonging to the lipo-
calin protein family [1]. ApoM is highly tissue-specific
protein mainly expressed in the liver and kidneys and
weakly expressed in the embryonic liver and other tis-
sues [2]. ApoM is the carrier of the biologically active
lipid mediator sphingosine-1-phosphate in high-density
lipoprotein cholesterol (HDL-C) and is implicated in
high-density lipoprotein (HDL) formation and HDL-
mediated reverse cholesterol transport [3–5]. Plasma
apoM (~23 mg/L) is mainly enriched in HDL-C and is
weakly present in low-density lipoprotein cholesterol
(LDL-C) and very low-density lipoprotein cholesterol
(VLDL-C) [3]. Hyperlipidaemia is often accompanied
with complex dyslipidaemia, such as increased LDL-C
and VLDL-C levels and low HDL-C levels, which are
associated with plasma apoM [6]. Increased plasma tri-
glyceride (TG) levels and significantly high plasma
apoM levels are detected in hyperlipidaemia mice with
defective low-density lipoprotein (LDL) receptor [7].
This observation suggests that plasma apoM concen-
trations may change in patients with hyperlipidaemia.
The link between apoM and type 2 diabetes mellitus
(T2DM) has also been investigated by using in vivo
and in vitro models. T2DM has emerged as an increas-
ing threat worldwide, and approximately 15 % of the
world’s population will manifest T2DM by 2025 [8].
Plasma apoM levels are increased in streptozotocin-
induced diabetic mice but are reduced with insulin
treatment [9]. Reduced plasma apoM levels are also
observed in another T2DM mouse model with high-
fat feed [10]. The latter observation is consistent with
a case–control study showing that plasma apoM
levels are lower in patients with T2DM than in con-
trols [11]. apoM expression is also altered in HepG2
cells with different concentrations of glucose medium
[9, 10]. The apoM promoter variant T-778C is associ-
ated with an increased risk of T2DM [12] and is
susceptible to type 1 diabetes mellitus [13]. T2DM is
often accompanied with hyperlipidaemia, which causes
high TG and LDL-C levels and low HDL-C levels
[6, 14]. Therefore, the specific effect of hyperlipid-
aemia on plasma apoM in patients with T2DM should
be investigated to confirm whether low plasma apoM
levels in T2DM are caused by diabetes or
hyperlipidaemia.
This study aimed to examine the apoM levels in pa-
tients with hyperlipidaemia, patients with T2DM and
hyperlipidaemia, and patients with T2DM but without
hyperlipidaemia through enzyme-linked immunosorbent
assay (ELISA). This study also aimed to determine the




The protocol was approved by the Medical Ethics Commit-
tee of the Wannan Medical College in China. All partici-
pants (age >18 years) provided written informed consent.
Subjects were recruited from The First Affiliated Yijishan
Hospital of Wannan Medical College as follows: patients
with hyperlipidaemia (n = 79), patients with T2DM but
without hyperlipidaemia (n = 125), patients with T2DM
and hyperlipidaemia (n = 98), and healthy controls (n =
105). All subjects were of Southern Han Chinese ancestry.
Healthy control group inclusion criteria include good
general health, no significant past medical history, and doc-
umented normal fasting blood glucose and glucose intoler-
ance. The exclusion criteria included active inflammatory/
infectious disease and history of atherosclerosis, stroke or
malignancy. T2DM was defined by the World Health
Organization criteria [fasting glucose ≥7.0 mmol/L
(126 mg/dL) or 2-h glucose ≥11.1 mmol/L (200 mg/dL)]
[15]. The exclusion criteria were non-type 2 diabetes (type
1 diabetes, gestational diabetes, and drug-induced dia-
betes), pregnancy, thyroid or liver disease, malignancy, azo-
temia, renal failure, fever, infection, and congestive heart
failure. Amongst the diabetic patients, those who used
insulin or thiazolidines were also excluded but the use of
antihypertensive drugs was allowed [11]. Hyperlipidaemia
was defined by the Adult Treatment Panel III of the
National Cholesterol Education Program [serum total TG
≥220 mg/dL (2.49 mmol/L) or serum total cholesterol
(TC) ≥240 mg/dL (6.24 mmol/L)] [16]. The exclusion cri-
teria were diabetes, pregnancy, thyroid disease, renal or
liver disease, malignancy, infection, fever, and congestive
heart failure. Hyperlipidaemic patients who used lipid-
lowering drugs were also excluded. Blood pressure was
measured on the right arm after 15 min rest in a sitting
position with a standard mercury sphygmomanometer. All
participants had an overnight fast and patients did not take
their usual medication and insulin before blood sampling.
Laboratory analyses
Blood samples were collected in one tube without anti-
coagulant and one EDTA-containing tube in the morning.
We allowed samples without anticoagulant to clot for 2 h
at room temperature before centrifugation at ~1000 × g
for 20 min at 4 °C. The plasma was divided into two tubes;
one tube was stored at −80 °C for later assay for apoM,
and the other tube with freshly prepared plasma was used
for plasma assay (excluding apoM). Whole blood samples
in EDTA-containing tubes were gently mixed fully before
haemoglobin A1c (HbA1c) assay.
Plasma creatinine (CR), cystatin C (CYS-C), superoxide
dismutase (SOD), fasting blood-glucose (FPG), and lipid
levels were determined using a Hitachi 7600 biochemistry
autoanalyser (Hitachi, Tokyo, Japan). CR, TG, TC, and
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HDL-C were analysed by enzymatic methods; LDL-C was
calculated by the Friedewald formula [17]. CYS-C, apoA-I,
apoB, and Lp(a) were analysed by immunoturbidimetric
assays; SOD by spectrophotometry; and FPG by glucose
oxidase method. All above reagents were purchased from
Beijing Leadman Biochemistry Co., Ltd., China. HbA1c
was measured by high performance liquid chromatog-
raphy using a Bio-Rad Variant II analyser (Bio-Rad La-
boratories, Hercules, CA, USA), and presented as NGSP
units (%) and with International Federation of Clinical
Chemistry units (mmol/mol) in parentheses.
Plasma apoM concentrations were assayed using a
commercial ELISA kit (Cloud-Clone Corp., Houston,
TX, USA) according to the manufacturer’s instructions.
The concentrations of apoM in the calibrator were
determined using a standard of known apoM concen-
trations. All samples were diluted at 1:5000 and ana-
lysed in duplicate. The range of the standard curve
was 0.312–20 ng/mL.
Statistical analysis
Continuous variables were normally distributed by
Kolmogorov–Smirnov test and provided as mean ± SD.
Categorical variables were expressed as percentages. Over-
all comparisons were performed with one-way ANOVA
and multiple comparison between the two groups was
derived from the LSD-t test. Differences in percentages of
variables were determined by χ2 test. The relationships be-
tween the index and apoM were examined using Pearson
linear regression analysis or multivariable linear regression
analysis. Two-sided P <0.05 was considered statistically
significant. All statistical analyses were performed with
SPSS version 16.0.
Results
Clinical characteristics and plasma variables including apoM
The plasma apoM concentrations were determined in
patients with hyperlipidaemia (n = 79), T2DM without
hyperlipidaemia (n = 125), T2DM with hyperlipidaemia
(n = 98), and healthy controls (n = 105). Comparisons of
the baseline characteristics and plasma parameters
amongst the four groups are shown in Table 1. No dif-
ference was observed in gender and age between the
four groups (P = 0.673; P = 0.347, respectively). Com-
pared with the healthy controls, patients with hyperlipid-
aemia had higher systolic blood pressure (SBP), diastolic
blood pressure (DBP), CR, TC, TG, apoA-I and apoB,
and lower HDL-C. SBP, DBP, and plasma FPG levels
were higher, whereas SOD, TC, HDL-C and apoA-I
levels were lower in the T2DM without hyperlipidaemia
group compared with healthy controls. The T2DM with
hyperlipidaemia group had higher CYS-C, TC, TG, and
apoB levels and lower FPG and HDL-C levels compared
with the T2DM without hyperlipidaemia group. SBP,
DBP, CYS-C, FPG, and LDL-C levels were higher,
whereas SOD, HDL-C, and apoA-I were lower in the
T2DM with hyperlipidaemia group compared with those
in the hyperlipidaemia group.
The plasma apoM concentrations were different in
four groups (P = 0.000, Table 1). The plasma apoM con-
centrations were on average 18 % higher in hyperlipid-
aemia patients (26.63 ± 10.35 ng/μL) compared with
healthy controls (22.61 ± 10.81 ng/μL; P <0.01; Fig. 1a).
However, the plasma apoM concentrations were lower
in the T2DM without hyperlipidaemia group (18.54 ±
10.33 ng/μL) and T2DM with hyperlipidaemia group
(19.83 ± 7.41 ng/μL) compared with those in the healthy
control group (22.61 ± 10.81 ng/μL; P <0.01, Fig. 1b;
P <0.05; Fig. 1c, respectively). The plasma apoM con-
centrations were lower in the T2DM with hyperlipid-
aemia group (19.83 ± 7.41 ng/μL) compared with those in
the hyperlipidaemia group (26.47 ± 10.18 ng/μL, P <0.001;
Fig. 1e). No statistical difference was observed in plasma
apoM concentrations between the T2DM with hyperlipid-
aemia group (19.83 ± 7.41 ng/μL) and T2DM without
hyperlipidaemia group (18.54 ± 10.33 ng/μL, P >0.05,
Fig. 1d) similar to apoA-I (1.29 ± 0.33 g/L vs. 1.28 ±
0.31 g/L, P >0.05, Table 1).
Association of plasma apoM with clinical and lipid
variables
The plasma apoM concentration was negatively correlated
with CYS-C in patients with hyperlipidaemia alone (r =
−0.250, P <0.05). However, apoM was positively correlated
with CYS-C in the T2DM with hyperlipidaemia group (r =
0.250, P <0.05) but was not correlated with CYS-C in the
other two groups. Amongst the lipid-related variables,
apoM was positively correlated with TC, HDL-C, and LDL-
C in the hyperlipidaemia group (r= 0.296, P <0.01; r =
0.352, P <0.01; and r = 0.369, P <0.01, respectively), T2DM
with hyperlipidaemia group (r = 0.300, P <0.01; r =
0.368, P <0.001; and r = 0.136, P >0.05, respectively),
T2DM without hyperlipidaemia group (r = 0.293, P <0.01;
r = 0.268, P <0.01; and r = 0.226, P <0.05), and in healthy
controls (r = 0.421, P <0.001; r = 0.495, P <0.001; and r =
0.259, P <0.001, respectively). Besides that, apoM was also
positively correlated with apoA-I in the T2DM with
hyperlipidaemia group (r = 0.030, P <0.01), T2DM without
hyperlipidaemia group (r = 0.347, P <0.001), and healthy
controls (r = 0.338, P <0.001), although such association
was not found in the hyperlipidaemia group (r = 0.123,
P >0.05). ApoM was also positively correlated with
apoB in the T2DM with hyperlipidaemia group (r = 0.220,
P <0.05) and healthy controls (r = 0.351, P <0.001). How-
ever, this association was not found in the hyperlipidaemia
alone group (r = 0.139, P >0.05) and T2DM without
hyperlipidaemia group (r = 0.052, P >0.05). ApoM was not
correlated with age, diabetes mellitus(DM) duration,
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ACR, FPG, HbA1c, CR, SOD, TG, and LP(a) in the four
groups (Fig. 2). By multivariate linear regression ana-
lysis, TC (β = 1.33, P = 0.007), HDL-C (β = 5.16, P =
0.016), and apoA1 (β = 5.18, P = 0.007) were the inde-
pendently influential factors for plasma apoM concen-
trations (Table 2). Meanwhile, T2DM itself (β = −3.09,
P = 0.005) was the independently negative factor for
apoM, whereas hyperlipidaemia (β = 3.43, P = 0.001)
was the positive factor. Moreover, no interaction was
observed between each other (Table 3).
Discussion
Our study mainly revealed that plasma apoM concentra-
tions in patients with hyperlipidaemia were higher than
those in healthy controls. Hyperlipidaemia was an inde-
pendent promoting factor of plasma apoM levels. Dia-
betes was also an independent inhibiting factor of
plasma apoM levels. These observations suggested that
hyperlipidaemia increased plasma apoM levels. There-
fore, low plasma apoM levels in T2DM patients were
not caused by hyperlipidaemia. Instead, low plasma
apoM levels were likely triggered by diabetes.
ApoM accounts for ~5 % of HDL-C and <2 % of LDL
and was one of the main components of HDL-C. The
apoM complex also contains HDL-C (apoA-I)- and
LDL-C (apoB)-related apolipoproteins [3]. Thus, plasma
apoM concentrations (~23 mg/L) were associated with
HDL-C, and also showed a strong association with LDL-
C, TC, apoA-I, and apoB [11, 18, 19]. This study also
confirmed the relationship between plasma apoM and
HDL-C, LDL-C, apoA-I, and apoB by univariate linear
regression analysis. In addition, apoM was independently
associated with HDL-C, TC, and apoA1 by multivariate
analyses. Hyperlipidaemia often displays reduced plasma
HDL-C and increased TC and LDL-C, which was associ-
ated with apoM [6, 14]. This study determined the
plasma apoM levels in patients with hyperlipidaemia and
found that hyperlipidaemia patients have marked apoM
levels than healthy controls. Moreover, hyperlipidaemia
was an independently promoting factor for plasma
apoM. Both the plasma apoA-I and apoM levels were
higher than those in healthy controls. Besides that, both
the plasma apoA-I and apoM levels were not statistically
different between the T2DM without hyperlipidaemia
groups and T2DM with hyperlipidaemia groups. Multi-
variate linear regression analysis also confirmed that the
plasma apoA1 level was the independent influential fac-
tor for apoM. Faber et al. had found that the plasma
concentrations of apoM decreased to 33 % of the normal
value in mice deficient in apoA-I [20]. In general, these










N (male/femal) 56/49 45/34 72/53 60/38 0.729
AGE (yrs) 54.65 ± 10.20 53.70 ± 10.61 55.30 ± 12.32 54.82 ± 11.79 0.805
SBP (mmHg) 118.00 ± 12.71 122.94 ± 14.01a 133.59 ± 18.36aaa 137.47 ± 19.74aaaccc 0.000
DBP (mmHg) 76.25 ± 8.37 81.15 ± 10.81aa 82.74 ± 10.84aaa 84.86 ± 10.27aaac 0.000
DM duration (yrs) - - 6.00 ± 5.55 6.46 ± 6.25
HbA1c (%(mmol/mol)) - - 9.3 ± 2.7(78 ± 30) 9.6 ± 2.0(81 ± 22)
Cr (umol/L) 63.88 ± 14.76 71.42 ± 14.69aa 66.88 ± 19.62 70.81 ± 26.75a 0.026
CYS-C (mg/ L) 0.98 ± 0.22 1.02 ± 0.28 1.00 ± 0.25bb 1.13 ± 0.39aaac 0.001
SOD (U/mL) 108.82 ± 10.88 103.85 ± 15.70 81.90 ± 19.01aaa 88.82 ± 32.17aaaccc 0.000
FPG (mmol/L) 5.35 ± 0.40 5.32 ± 0.65 8.72 ± 3.09aaabbb 10.14 ± 3.22aaaccc 0.000
TC (mmol/L) 4.31 ± 0.57 4.85 ± 1.23aa 4.00 ± 0.85abbb 5.00 ± 1.53aaa 0.000
TG (mmol/L) 1.19 ± 0.45 3.19 ± 0.97aaa 1.27 ± 0.50bbb 3.50 ± 1.19aaac 0.000
HDL-C (mmol/L) 1.43 ± 0.24 1.22 ± 0.22aaa 1.26 ± 0.34aaabbb 1.12 ± 0.25aaac 0.000
LDL-C (mmol/L) 2.33 ± 0.44 2.20 ± 0.90 2.36 ± 0.69b 2.62 ± 0.93aaccc 0.002
apoA-I (g/L) 1.66 ± 0.29 1.86 ± 0.31aaa 1.28 ± 0.31aaa 1.29 ± 0.33aaaccc 0.000
apoB (g/L) 0.78 ± 0.22 1.11 ± 0.20aaa 0.77 ± 0.26bbb 1.04 ± 0.36aaa 0.000
LP(a) (mg/L) 124.24 ± 106.99 102.60 ± 109.03 143.13 ± 133.09 126.92 ± 140.27 0.160
Data mean ± SD. N number, M male, F female, SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c glycated hemoglobin A1c, is presented as NGSP
units (%) and with IFCC units (mmol/mol) in parentheses., apo apolipoprotein; P value comparisons among four groups by one-way ANOVA, avs. healthy
control group, aP <0.05, aaP <0.01, aaaP <0.001, bvs. T2DM with hyperlipidaemia group, bP <0.05, bbP <0.01, bbbP <0.001, cvs. hyperlipidaemia group, cP <0.05,
ccP <0.01, cccP <0.001
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observations showed that the synthesis, secretion or
turnover of apoM in plasma may to a certain extent de-
pend on apoA-I. The fractional catabolic rate of apoA-I
is significantly increased, whereas the absolute produc-
tion of apoA-I is inhibited in T2DM patients and thus
causes a decrease in plasma apoA-I levels [21–23].
Meanwhile, apoA-I and apoM mainly exist in HDL-C
[24], and a connection is observed between apoM and
apoA-I metabolism [20]. This condition suggests that
the the metabolism of apoM in T2DM may be partly
similar to apoA-I.
In two independent case–control studies, the mean
HDL-C level is significantly lower in coronary heart dis-
ease patients than in control subjects, but the mean
apoM levels do not significantly differ between the two
groups [25]. Similarly, the apoM levels in T2DM with
Fig. 1 Scatter plot showing the apoM concentrations. hyperlipidaemia(n = 79), T2DM without hyperlipidaemia (n = 125), T2DM with hyperlipidaemia
(n = 98), Healthy controls (n = 105). a only hyperlipidaemia group vs. healthy controls group; (b) T2DM without hyperlipidaemia group vs. healthy
controls group; (c) T2DM with hyperlipidaemia group vs. healthy controls; (d) T2DM without hyperlipidaemia group vs. T2DM with hyperlipidaemia
group; (e) T2DM with hyperlipidaemia group vs. only hyperlipidaemia group. The bars indicate the mean values. *P <0.05
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hyperlipidaemia patients also showed no significant dif-
ference compared with patients of T2DM without hyper-
lipidaemia, whereas the HDL-C level was significantly
lower in the former, suggesting that plasma apoM levels
were also correlated with other factors, such as LDL-C,
TC, and apoA-I, except for HDL-C [11, 18, 26]. These
results agree with data from Christoffersen et al., which
indicates that the mice with defective LDL receptor
whose plasma TG levels were increased had significantly
high plasma apoM and the large fraction of apoM was
associated with LDL-C/CM particles and not HDL-C
[7]. Meanwhile, Kurano observed that in LDL receptor-
overexpressing mice, the plasma apoM levels were
decreased [27]. Karuna et al. also found that apoM is
mainly present in plasma LDL-C and has a negative cor-
relation with HDL-C concentration in individuals with
low HDL-C because of lecithin–cholesterol acyltransfer-
ase deficiency [28]. A possible explanation for the above
results and the relationship between hyperlipidaemia
and plasma apoM levels could be that apoM can rapidly
exchange between HDL-C and VLDL-C/LDL-C particles
in vivo [7]. This condition leads to the VLDL/LDL pool
of apoM that is replenished from the HDL in hyperlipid-
aemia patients with marked plasma VLDL/LDL levels.
Hepatic apoM gene expression and plasma level were
significantly low in mouse models of alloxan-induced
diabetes and hyperglycaemia-induced diabetes [29, 30].
Meanwhile, the plasma apoM concentration was lower
in patients with T2DM compared with those in healthy
controls [31]. This study confirmed that the plasma
apoM levels were reduced in T2DM patients with or
without hyperlipidaemia than those in healthy controls.
Multivariate analyses showed that diabetes itself was an
independently inhibiting factor for plasma apoM levels.
However, the specific reasons are still unclear. Previous
study reported that insulin and high glucose (30 mmol/L
glucose) can downregulate apoM expression in HepG2
cell culture and diabetic mouse [26]. However, a recent
Fig. 2 Univariate correlation coefficients (Pearson’s r) for associations of plasma apoM with clinical variables and plasma parameters. hyperlipidaemia
(n = 79), T2DM without hyperlipidaemia (n = 125), T2DM with hyperlipidaemia (n = 98), and healthy controls (n = 105). The bars indicate the mean
values. *P <0.05;**P <0.01; ***P <0.001
Table 2 Influential factors for apoM:multivariable linear
regression analysis
β SE t P value 95 % Confidence Interval for β
TC 1.33 0.49 2.70 0.007 0.36 2.29
HDL 5.16 2.14 2.41 0.016 0.94 9.38
apoA1 5.18 1.93 2.69 0.007 1.39 8.97
β unstandardized coefficients, SE standardized error, β’
standardized coefficients
Table 3 T2DM and hyperlipidaemia are independently
influential factor for apoM
β SE t P value 95 % Confidence
Interval for β
T2DM −3.09 1.09 −2.83 0.005 −5.23 −0.94
hyperlipidemia 3.43 1.01 3.40 0.001 1.44 5.41
β unstandardized coefficients, SE standardized error, β’ standardized coefficients
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research found that the influences of 13.5 g/dL glucose,
9 and 4.5 g/dL glucose on apoM in HepG2 cell were not
statistically different. Whereas, the medium apoM and
cellular apoM levels significantly increased accompanied
with elevator glucose (0, 1.0, and 4.5 g/dL). Besides, the
plasma apoM levels were higher in streptozotocin-
induced diabetes mice than those in control mice [9].
Hyperglycaemia can stimulate the hexosamine pathway
and cause an increase in endogenous glucosamine levels
[32], but both exogenous and endogenous glucosamines
can increase the apoM expression in HepG2 cells and in
rat models [33]. Our study did not observe a correlation
between plasma apoM and glucose/HbA1c in healthy
subjects or T2DM patients similar to that described in
a previous report [31]. Previous studies indicated that
the effects of blood glucose concentrations on apoM
level are complex. Glucose concentrations, glucose
metabolic products, and diabetes pathogenesis can in-
fluence apoM metabolism.
Family history of diabetes and pre-diabetic condition
can be accounted for an increase in the risk of insulin
resistance and high blood glucose concentrations, which
can induce endothelial impairment and exacerbate dysli-
pidaemia and atherosclerotic lesions [34]. Interestingly,
nutraceuticals and functional food ingredients, such
theaflavins and proanthocyanidins, which elicit lipid-
lowering effects, may also influence plasma apolipopro-
tein levels [35].
Conclusions
In conclusion, plasma apoM concentrations were higher
in patients with hyperlipidaemia than in healthy subjects.
Hyperlipidaemia was an independent promoting factor of
plasma apoM levels. Diabetes was also an independent
inhibiting factor of plasma apoM levels. Therefore, low
plasma apoM levels in T2DM patients were likely caused
by diabetes but were unlikely induced by hyperlipidaemia.
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